Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Travis Tidwell

Podiatrist Waterloo, IA Doctor of Podiatric Medicine

NPI 1043627292 CMS profile 706805

2710 Saint Francis Dr Ste 510, Waterloo, IA 50702

Open in the dashboard

General payments

$32,557

210 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Travis Tidwell of Waterloo, IA is reported in the CMS Open Payments database as having received $32,557 across 210 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,633 16
2024 General $11,126 34
2023 General $7,056 30
2022 General $29 2
2021 General $3,381 28
2020 General $2,116 23
2019 General $7,216 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Travis Tidwell
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Travis Tidwell were reported at $1,633. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Travis Tidwell Podiatrist median Middle half National median
2019 $7,216 $196 $72–$601 $163
2020 $2,116 $118 $38–$335 $114
2021 $3,381 $169 $57–$573 $132
2022 $29 $220 $74–$782 $149
2023 $7,056 $208 $71–$635 $160
2024 $11,126 $237 $87–$681 $164
2025 $1,633 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $12,941 97 payments
  2. International Life Sciences $11,919 5 payments
  3. Wright Medical Technology, Inc. $6,725 44 payments
  4. Organogenesis Inc. $537 42 payments
  5. DePuy Synthes Sales Inc. $110 4 payments
  6. Zimmer Biomet Holdings, Inc. $87 3 payments
  7. Melinta Therapeutics, Inc. $56 4 payments
  8. Smith+Nephew, Inc. $42 2 payments
  9. Boston Scientific Corporation $29 2 payments
  10. Integra LifeSciences Corporation $19 1 payment
  11. Other $91 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $16,310 61 payments
  2. Consulting Fee $10,800 3 payments
  3. Food and Beverage $5,448 146 payments
Products named General payments · program years 2019–2025
  1. FLEXBAND Orthopaedics $6,452 2 payments
  2. PROSTEP Trauma & Extremities $5,168 29 payments
  3. FLEXBAND $3,667 2 payments
  4. SALVATION $2,492 19 payments
  5. INBONE $2,267 14 payments
  6. INFINITY Foot And Ankle $1,873 9 payments
  7. INFINITY Trauma & Extremities $1,800 15 payments
  8. PROstep Foot And Ankle $1,302 13 payments
  9. PROPHECY $860 8 payments
  10. MIS Instrumentation $809 1 payment
  11. Other $4,453 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

148

Median for Podiatry: 160

Drug cost

$1,258

Median for Podiatry: $2,368

Branded share of claims

8.8%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 69 $478
Gabapentin Generic 31 $343
Terbinafine Hcl Generic 22 $261
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 13 $98
Cephalexin Generic 13 $78

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$111,956

Of which drugs: $78

Medicare patients

434

Average age 76

Services billed

2,172

218 women, 216 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 38%
Ischemic heart disease 30%
Chronic kidney disease 28%
Depression 25%
Atrial fibrillation 22%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 18 290 $30
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 28 48 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record